Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• Consumer prices have risen notably during recent months, linked by many to the United States’ involvement in launching the Iran War and the resulting strictures on international energy transports
• Gold bullion prices have, with expected variations, enjoyed a significant rise since January of last year, and the precious metal is anticipated to continue acting as a long-term “hedge” or “safe haven” against inflationary pressures
• Near-term gold producer LaFleur Minerals is preparing to restart its recommissioned Beacon Gold Mill and to draw on mineralized material from its Swanson Gold Deposit in the Abitibi Greenstone Belt
• LaFleur’s all-in sustaining cost estimates anticipate profits based on base case pricing of gold from before the recent growth factors, and economists expect the foundational upward pressure on gold prices to persist

Consumers in the United States have watched prices grow at a “moderate to strong pace” in recent weeks as an apparent response to the ongoing Iran War, according to federal policy makers (https://ibn.fm/h06l8), which has a potential downstream effect on investor interest in precious metals such as gold that enjoy a reputation as a long-term “hedge” against currency debasement and inflation (https://ibn.fm/EeHdo).

The Iran War is the most recent in a series of incidents in which the U.S. government has used or threatened to use military force against other nations. Inflation fears, shifting economic policies and the increasing geopolitical tensions accompanying administration activities since January 2025 have been met with repeated record price spikes in the price of gold, taking it from a strong baseline of about $2,600 per ounce to over $5,600 per ounce in a year’s time (https://ibn.fm/RU486).

While gold prices have seen some instability during recent months as the market factors in short-term conditions, gold continues to remain far above the prices it recorded in previous years (https://ibn.fm/NY6Vq). And economists expect Inflation to worsen (https://ibn.fm/sNNRS).

Near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is preparing to take advantage of the market’s interest in gold as well as its own strategic financing and asset acquisition. LaFleur is on the cusp of restarting its Beacon Gold Mill during the next few months (https://ibn.fm/oF93j), initially drawing on approximately 100,000 metric tonnes from a bulk sample from its nearby Swanson Gold Project to incrementally increase the mill’s capacity from 750 metric tons per day (“TPD”) to 1,250 TPD. 

LaFleur’s Beacon Gold Mill, Swanson Gold Project and newly acquired McKenzie East Gold Project are all situated within the prolific Abitibi Greenstone Belt within southwestern Quebec, which is a premier global mining district renowned for its massive gold, copper, zinc, and silver deposits as one of the world’s largest, oldest and most richly mineralized Archean greenstone belts (https://ibn.fm/9Cgml).

Gold miners continue to anticipate price growth during the coming months despite the recent instability in the market. Metals consultancy Metals Focus’ newly released Gold Focus 2026 report states “We are confident that, once the Iran war dust settles, gold will resume its bull run. Crucially, all other factors that underpinned gold last year are likely to remain in place over the rest of 2026 and beyond,” as reported by The Northern Miner (https://ibn.fm/JS8vB).

LaFleur CEO and Director Paul Ténière told investors in March that the company expects to be easily profitable, given the market factors and forecasts in company with LaFleur’s low CAPEX plan.

“We’re looking at an all-in sustaining cost of just under $1,600 an ounce,” he said. “This is at a base case of $2,750. Our technical report will be looking at a sensitivity of up-to-$5,000 gold. … We can certainly be running (our Swanson gold project) for the next few years and be a very cost-effective and profitable operation.”

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform.
• Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment.
• Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.

When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself. Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform.

Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the bookmark and highlighter system layered on top of that manual, determined by a combination of inherited tendencies, age, diet, exercise, sleep, stress, smoking and other lifestyle factors, and environmental exposures.

“In the case of heart disease, the reason why epigenetics becomes really powerful is, if we took a step back and we had to dissect heart disease, about 20% of it is genetic,” explains Cardio Diagnostics cofounder and CEO Dr. Meesha Dogan. “So, when we talk about family history, a lot of times we’re talking about genetics. But if you pause, a lot of people would realize the way you eat, the way you grew up, your certain environment and lifestyle, that’s also family history. 

Genetics alone is not your family history.

“The reason I emphasize lifestyle and environment is because that’s what epigenetics captures,” Dogan continues. “It captures what we’re doing in our day-to-day lives, whether it’s a certain behavior, what we’re eating, what’s happening around us [and] how is that affecting this specific DNA biomarker that is dynamic in nature. And that’s critical for heart disease because 80% of heart disease is nongenetic and largely comes from our lifestyle and environment.”

As a result, Dogan notes, looking at an individual person’s epigenetics can provide invaluable insight into the impact of their behavior and environment. “The other aspect that really excites me about epigenetics in the context of heart disease is that . . . as much as its pointing out a problem, there are insights into where the problem is coming from. And that is powerful because we’re not just pinpointing a problem, but inherently built into that information is some level of solution,” she states.

This is part of why epigenetics is a foundational piece of Cardio Diagnostics’ approach. The company has built its commercial testing portfolio around the concept that genetics is inherited and is not modifiable while epigenetics reflects how an individual’s lifestyle and environment shape the expression of their genes.

The company’s Epi+Gen CHD test analyzes a combination of epigenetic and genetic biomarkers to assess a patient’s three-year risk of a coronary heart disease event, including a heart attack. Research indicates that DNA methylation patterns can reflect environmental exposures and lifestyle influences while also serving as early indicators of disease risk. Because epigenetic markers can change over time, they offer a more dynamic view of cardiovascular health than genetics alone. The company’s PrecisionCHD test similarly combines epigenetic and genetic information, supported by artificial intelligence, to help detect signal associated with coronary heart disease.

For patients and healthcare providers alike, the practical takeaway is straightforward. Genetics is the starting point, not the whole picture. Choices made every day, from what is eaten and how often someone moves to whether they smoke or how they manage stress, leave a measurable trace on the genome itself. Cardio Diagnostics’ approach is rooted in the idea that reading that trace, alongside genetic information, offers a more current and more complete view of cardiovascular risk than either piece of information could provide on its own.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• SS Innovations reported record first-quarter 2026 revenue of $11.1 million, up 116.8% year over year, driven by growing adoption of its SSi Mantra surgical robotic system.
• The installed base reached 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed.
• Regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanded the company’s international market access during the quarter.
• SS Innovations recently completed the world’s longest-distance robotic cardiac telesurgery in history, demonstrating the capabilities of its remote surgery platform.
• The company continues pursuing regulatory clearance in both the United States and Europe while expanding its presence in emerging healthcare markets.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies to aid in cardiac and other surgeries, including telesurgeries, reported record first-quarter 2026 financial results, highlighting accelerating commercial adoption of its SSi Mantra surgical robotic platform as the company continues expanding internationally and pursuing regulatory approvals in major healthcare markets.

According to the company’s first-quarter earnings announcement, revenue increased 116.8% year over year to $11.1 million, driven primarily by higher installations of the SSi Mantra surgical robotic system and increased procedure volumes. Gross profit rose to $5.3 million from $1.1 million a year earlier, while gross margin expanded to 48.0%, reflecting greater operating scale and manufacturing efficiency (https://ibn.fm/z0I6H).

The company also reported continued improvement in its financial position, ending the quarter with approximately $16 million in cash and cash equivalents and no long-term debt. Earlier this year, the company completed a private placement that generated approximately $18.6 million in gross proceeds to support future growth initiatives.

During the quarter, SS Innovations installed 26 additional SSi Mantra systems, representing a 73% increase compared with the first quarter of 2025. As of March 31, the company’s installed base had grown to 194 systems operating across eleven countries. Clinical utilization also continued to increase. The company reported that surgeons have now completed 9,744 procedures using the SSi Mantra platform, including 482 cardiac surgeries, 161 pediatric procedures and 157 telesurgeries.

Chief Executive Officer Dr. Sudhir Srivastava said the results reflected growing acceptance of the platform among hospitals and physicians, citing its combination of advanced robotic capabilities, ease of use, integrated training features, and lower cost relative to many established robotic surgery systems.

The first quarter also brought several regulatory milestones. SS Innovations received approval for the SSi Mantra system in Sri Lanka and Kenya while Indonesia and the Philippines authorized the platform for telesurgery applications. Those approvals form part of the company’s broader strategy to expand access to robotic surgery in regions where healthcare providers have historically faced financial barriers to adopting robotic technologies.

The company is also working toward entry into larger regulated markets. Management expects the U.S. Food and Drug Administration to complete review of its 510(k) submission during 2026 while continuing efforts to obtain CE Mark certification for the European Union. “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets,” Dr. Srivastava said. “We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.”

More recently, SS Innovations attracted attention with another striking demonstration of its telesurgery capabilities. In early June, the company announced the successful completion of what it described as the world’s longest-distance robotic telesurgery, performed over approximately 12,500 miles (20,000 kilometers) between Guyana and India (https://ibn.fm/2wm2B).

The cardiac operation was performed by Dr. Srivastava, operating remotely from Guyana in South America, using the company’s portable SSi MantrAsana tele-surgeon console. Robotic equipment positioned with the patient in India replicated the surgeon’s delicate movements in real time while operating across an international fiber-optic network. The procedure involved a cardiac operation known as a Left Internal Mammary Artery (“LIMA”) takedown. According to the company, the system operated with network latency of approximately 290 to 300 milliseconds while maintaining surgical precision.

Although telesurgery currently represents a relatively small portion of the company’s overall commercial applications, management views the technology as an important long-term opportunity for expanding access to specialized surgical expertise in many remote and underserved regions. To date, SS Innovations reports that 173 robotic telesurgeries have been completed using the SSi Mantra platform, including 22 cardiac telesurgeries. According to the company, the SSi Mantra remains the only robotic surgical system that has been used for robotic cardiac telesurgery.

The company’s broader business remains centered on hospital adoption of robotic systems to aid in a wide variety of surgeries. The SSi Mantra platform is designed as a modular robotic surgery system capable of supporting three to five robotic arms, depending on procedural requirements. The system includes an open-console surgeon workstation, three-dimensional 4K visualization, integrated imaging capabilities, and a growing portfolio of more than 40 robotic surgical instruments supporting multiple specialties.

Unlike many robotic surgery platforms initially focused on a narrow range of procedures, the SSi Mantra has been clinically validated across more than 170 surgical procedures in India, including general surgery, gynecology, urology, thoracic surgery, cardiac surgery, pediatric procedures and ear, nose and throat operations.

The company’s strategy emphasizes affordability alongside functionality. By developing a lower-cost robotic platform, SS Innovations aims to broaden adoption among hospitals that have traditionally found robotic surgery systems financially difficult to acquire. That approach may be particularly relevant across emerging healthcare markets, where demand for minimally invasive surgery continues to grow while healthcare budgets remain constrained.

For more information, visit the company’s website at www.SSInnovations.com.

Update: 

As of June 22, 2026, the cumulative number of multi-specialty procedures completed with the SSi Mantra surgical robotic system totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.

• Market Street Capital has evolved from its origins in investor relations into a diversified financial services platform spanning advisory, investment banking, capital raising, restructuring, valuation, and real estate services.
• The company focuses on established middle-market businesses with enterprise values ranging from $10 million to $1 billion, serving a defined client base that frequently requires sophisticated financial and strategic advisory services.
• Market Street Capital’s platform combines strategic advisory and transaction execution capabilities, allowing the firm to support clients across multiple stages of the corporate lifecycle.
• The leadership team brings experience across capital markets, structured finance, mergers and acquisitions, private credit, public company transactions, corporate development, and business operations.
• Institutional-grade compliance and governance standards are embedded across the firm’s operations, with regulated activities conducted through established broker-dealer and investment advisory frameworks.
• The company has advised on more than $3 billion in completed transactions, reports a multi-billion-dollar active pipeline, and maintains relationships across institutional investors, private equity firms, family offices, lenders, and strategic acquirers.

Market Street Capital is a boutique capital markets and financial advisory firm that works with established middle-market businesses navigating pivotal moments in their development. The company serves founder-led, family-owned, and private equity-backed enterprises seeking guidance on strategic transactions, capital formation, governance matters, and long-term value creation.

Founded in 2012 as Market Street Investor Relations, the firm initially focused on helping companies build investor confidence and strengthen public perception. In 2021, it rebranded as Market Street Capital to reflect its expansion into a broader financial services platform encompassing advisory, investment banking, wealth management, and private equity capabilities.

Today, Market Street Capital combines institutional-quality expertise with the personalized service of a boutique firm, delivering strategic insight and disciplined transaction execution across the corporate lifecycle.

The company is headquartered in Houston, Texas, and maintains additional locations across California, Louisiana, New York, and Switzerland.

Advisory & Capital Markets Platform

Market Street Capital provides strategic advisory services to boards, executives, shareholders, and investors facing significant business, governance, and capital allocation decisions. The firm’s Strategic Planning & Advisory practice supports clients through restructurings, recapitalizations, divestitures, joint ventures, executive leadership transitions, governance initiatives, and public market readiness efforts. The practice also advises on strategic alternatives, capital structure optimization, succession planning, and post-transaction integration.

The company’s investment banking platform spans mergers and acquisitions, private equity raises, debt capital markets, specialty lending, valuation services, and restructuring advisory. Market Street Capital advises clients on buy-side and sell-side transactions, capital raising initiatives, debt financing structures, liquidity events, and special situations requiring complex stakeholder coordination. The firm’s valuation capabilities support transaction planning, capital events, strategic decision-making, litigation matters, and the valuation of businesses, securities, financial instruments, and tangible and intangible assets.

Market Street Capital also assists companies preparing for the public markets through IPO readiness assessments, capital structure planning, syndicate organization, valuation strategy, investor positioning, and roadshow preparation. Beyond traditional corporate advisory services, the firm maintains a real estate practice focused on capital markets advisory, strategic planning, recapitalizations, restructurings, acquisitions, dispositions, and financing solutions across multiple property sectors. The firm’s wealth management platform complements these capabilities, offering qualified investors tax-efficient access to private market strategies, including insurance dedicated fund (“IDF”) and credit enhancement fund structures.

Market Opportunity

Market Street Capital focuses on established businesses with enterprise values ranging from $10 million to $1 billion, including founder-led, private equity-backed, and family-owned companies pursuing growth initiatives, recapitalizations, ownership transitions, liquidity events, and strategic transactions. The firm’s advisory and capital markets platform is designed to support clients through a broad range of financial and operational inflection points.

According to PwC, global M&A deal values increased 36% between 2024 and 2025, driven in part by a rise in transactions valued at more than $5 billion. PwC reported that megadeals increased from 63 transactions in 2024 to 111 transactions in 2025, while the Americas accounted for approximately 60% of global deal value. The firm also noted that deal values in the Americas increased 55% year over year, reflecting continued activity across the transaction landscape despite broader economic and geopolitical uncertainty. This sustained level of deal activity, alongside generational ownership transitions occurring across the middle market, supports continued demand for the independent advisory and capital markets services Market Street Capital provides.

Leadership Team

Stan Abiassi, Founder and CEO, brings more than 30 years of experience helping businesses pursue transformational growth and navigate capital markets opportunities. Prior to founding Market Street Capital, he built and led a small-cap and middle-market firm that assisted companies through public listings, sales at premium valuations, strategic transactions, and other significant corporate milestones. During the past 14 years, he has led Market Street Capital’s efforts in capital raising, strategic partnerships, initial public offerings, and merger and acquisition transactions. He holds Series 7, 63, and 65 licenses and is widely regarded as a trusted advisor within the business and investment community.

Daniel Langston, Managing Partner and Chief Business Officer, is an entrepreneur and executive whose career has spanned entertainment, sports marketing, real estate, technology, and business development. His experience includes founding and exiting a national sports marketing firm operating in 12 cities, leading a 240-person sales organization serving more than 800 clients, consulting across multiple industries, and serving as chairman of a technology company. At Market Street Capital, he focuses on strategic growth, innovation, and business development initiatives.

Dourgam Kummer, Managing Partner and Chief Financial Officer, has more than 30 years of executive leadership and strategic development experience focused on structured finance, mergers and acquisitions, corporate restructuring, and multinational operations. His background includes overseeing international business units, managing teams of more than 100 employees, and helping guide a technology company through an initial public offering on both the Swiss Stock Exchange and Nasdaq. He has also served on multiple boards and brings experience in venture capital, corporate finance, and strategic management.

Ari Raskas, Head of Credit, is a credit investor and entrepreneur with more than 16 years of experience structuring, financing, and operating both private and public companies. His experience includes sourcing, underwriting, and executing complex credit and capital markets transactions, as well as raising capital for growth-oriented businesses. Throughout his career, he has been credited with helping growth companies secure more than $2 billion in new capital across industries including healthcare, technology, education, and natural resources. His prior leadership roles include positions at RK Equity Advisors and Broadband Capital Management.

Amanda Abiassi, Partner and Head of Corporate Development, leads business development strategy, corporate partnerships, and client engagement initiatives for Market Street Capital. She brings more than 20 years of experience in event planning, fundraising, organizational growth, and relationship development. Her work focuses on strengthening strategic partnerships, supporting client growth initiatives, and advancing the company’s mission of bridging Wall Street expertise with Main Street values through long-term relationship building and organizational development.

For more information, visit the company’s website at https://www.marketstreetcp.com.

NOTE TO INVESTORS: The latest news and updates relating to Market Street are available in the company’s newsroom at https://ibn.fm/MarketSt

• For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops.
• What makes CHD numbers particularly troubling is that so much of this is preventable.
• Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level.

Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops, and the data increasingly shows the gaps this leaves behind. Coronary heart disease is the most common form of cardiovascular disease (“CVD”) and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. For many patients, by the time a traditional risk factor shows up, the disease may already be well underway.

The scale of the problem is significant. In the United States, one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. The human toll is even starker. Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. There is also a lesser-known subset of the disease that adds further complexity. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (“INOCA”), a subset of CHD.

What makes these numbers particularly troubling is that so much of this is preventable. An estimated 80% of cardiovascular disease is preventable through early detection and proactive management, yet the tools used to identify who needs that early intervention are missing more cases than they catch. A risk calculator with an average sensitivity of 39% means that for every 100 people who will experience a CHD event, on average, 39 of them would be flagged. Many patients walk out of a routine checkup with a clean bill of health, even as the disease quietly progresses.

This is the gap that Cardio Diagnostics is focusing on addressing. Rather than relying solely on the conventional risk factor checklist, the company has developed clinical tests rooted in genetics, the DNA blueprint, and epigenetics, the field that examines how genes are expressed and regulated at the molecular level, often in response to lifestyle, environment and underlying disease processes long before signs and symptoms may appear.

The company’s flagship offering, Epi+Gen CHD, is a blood-based test that assesses a patient’s three-year risk of experiencing a coronary heart disease event, including a heart attack, by analyzing a targeted panel of three epigenetic and five genetic biomarkers. Because these biomarkers can reflect biological changes happening regardless of the shifts in traditional markers, the test is designed to identify risk in people who may otherwise be classified as lower risk using standard tools.

The company also offers PrecisionCHD, which is also a clinical blood test designed to aid in the diagnosis of CHD. This solution analyzes a targeted panel of six epigenetic and 10 genetic biomarkers that are closely associated with CHD. Using artificial intelligence, the test predicts CHD signal with high sensitivity, supporting management of stable ischemic heart disease.

These tests are not a wholesale replacement for existing cardiology practice but rather an attempt to fill a documented and substantial blind spot. Traditional risk factors remain clinically relevant and continue to play a role in patient evaluation. What molecular biomarker testing adds is a second lens, one that can pick up signals the first lens was never built to detect.

For a disease that often gives no warning before a heart attack occurs, any tool that shifts the odds toward earlier detection carries meaningful weight. With more than 800,000 CHD events annually, and one in five heart attacks occurring without warning, and with the majority of cardiovascular disease considered preventable when caught early, the cost of missed detection is measured not just in healthcare dollars but in lives.

Cardio Diagnostics is positioning its epigenetics-based testing as part of the answer to that gap, offering physicians and patients a way to see risk that conventional tools have consistently struggled to capture. As the data on traditional risk calculator performance continues to circulate among clinicians and researchers, the case for incorporating molecular diagnostics into routine cardiovascular testing may continue to build.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• APUS is aligning its treasury strategy with the shift from Bitcoin ownership to Bitcoin productivity via yield and digital credit markets
• MindWave is focused on institutional-grade custody, treasury optimization and compliant digital asset infrastructure
• The updates highlight MindWave’s broader mission: to enable institutions to transform Bitcoin from a passive reserve asset into productive, yield-generating capital

The digital asset industry is entering a new phase of development. While early blockchain adoption was largely driven by speculation and asset appreciation, today’s market is increasingly focused on building sustainable financial infrastructure capable of supporting long-term institutional participation. Companies that can facilitate this transition are beginning to occupy an increasingly important role within the evolving digital asset ecosystem.

MindWave Innovations Inc. (NYSE American: APUS) is positioning itself within a structural transformation in corporate Bitcoin strategy, as institutional players move from simply holding BTC on balance sheets to actively deploying it within yield-generating financial systems. This shift highlights a broader maturation of the digital asset ecosystem, where Bitcoin is increasingly treated not only as a store of value but also as programmable collateral capable of supporting new forms of credit creation and liquidity generation.

This shift is becoming evident as traditional financial institutions quietly adopt technologies and operational frameworks that first emerged within decentralized finance (“DeFi”). What began as experimental blockchain-based lending, staking, liquidity provisioning and treasury management systems has evolved into a broader blueprint for more efficient capital markets. As a result, the conversation is moving beyond simple digital asset ownership and toward how these assets can be productively deployed within transparent, yield-generating financial ecosystems.

The result is an industry-wide transition from speculative participation toward operational utility, where digital assets function not only as stores of value but as productive components of broader financial infrastructure.

Companies developing institutional-grade digital asset infrastructure are becoming increasingly important participants in the industry’s evolution. As organizations seek secure custody, transparent treasury management yield optimization and regulatory compliance, demand is growing for platforms capable of supporting digital assets as productive financial instruments rather than passive holdings.

MindWave’s recent strategic initiatives reflect many of these emerging priorities. The company has been advancing a platform designed to support institutional participation in digital asset treasury management through board-controlled custody frameworks, insured treasury wallets, audit-ready reporting, AI-powered treasury optimization tools and structures designed for corporate oversight. As the Bitcoin treasury landscape expands and digital credit markets continue to scale, MindWave appears positioned to participate in a broader evolution of corporate finance, one in which Bitcoin is increasingly utilized as productive capital rather than simply held as a reserve asset.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions.
• The  milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark.
• Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions.

Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal — generating reliable evidence that a new drug, device or diagnostic tool is both safe and effective. Without this structured process, promising laboratory discoveries would never make the leap to treatments that physicians can confidently prescribe and patients can trust. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, recently announced in its collaborative imaging study with Massachusetts General Hospital (“MGH”) that the study has reached the halfway point in patient enrollment and early imaging results could support development of its multiple sclerosis drug candidate: Lucid-MS.

Studies of this kind sit at the center of how medicine advances. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions: Does the approach work as intended? Is it safe? And can it reliably detect or measure what researchers claim it can? Imaging studies, in particular, often serve a dual purpose. They can validate new diagnostic tools while also generating data that helps assess how well an experimental treatment is performing inside the body.

This is especially important in diseases such as multiple sclerosis, where progression and treatment response have traditionally been difficult to measure with precision. Standard imaging techniques can show overall lesion activity, but they often cannot directly distinguish between damaged myelin with intact underlying nerve fibers and more severe, irreversible nerve damage. A tool capable of making that distinction would give researchers a clearer picture of whether a therapy is genuinely protecting or repairing the nervous system, rather than simply masking symptoms.

That clarity matters not just for individual patients but for the broader drug-development pipeline. Regulatory agencies increasingly look for objective, quantifiable biomarkers that can demonstrate a drug’s biological effect, not just its impact on symptoms. Qualified biomarkers can reduce uncertainty in regulatory decision-making, support more efficient clinical trial design and help identify patient populations most likely to demonstrate treatment effects, potentially reducing study size and duration while providing earlier evidence of drug activity. For smaller biopharmaceutical companies developing novel mechanisms, having access to this kind of precise measurement tool can be a meaningful advantage in both clinical development and conversations with regulators and potential partners.

Quantum BioPharma’s MGH collaboration is built around a novel positron emission tomography (“PET”) imaging technique using the tracer [¹⁸F]3F4AP, developed by Dr. Pedro Brugarolas, an investigator in the radiology department at MGH and assistant professor at Harvard Medical School. The technique is designed to directly assess demyelinated neurons that still have intact axons, offering a more precise way to track demyelination, the process underlying MS, than has previously been available.

Highlighted in the announcement is that patient enrollment in the study has now reached its halfway mark. Reaching the midpoint of enrollment is a meaningful operational step in any clinical study, as it indicates the trial is progressing on schedule and moving closer to having a dataset large enough to draw more confident conclusions.

The second highlight concerns the imaging results themselves. According to the company, the first cohort of participants has been imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. If these early findings hold up as enrollment continues, the company believes the imaging approach could provide a more direct and quantitative way to measure myelin loss and repair over time.

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Dr. Andrzej Chruscinski, VP of scientific and clinical affairs at Quantum BioPharma. “PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination, providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies such as Lucid-MS that aim to protect and restore the myelin sheath in MS.”

Brugarolas stated that being able to directly quantify demyelinated lesions with intact axons in living patients addresses an important gap in MS research. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS,” he said.

The company noted that this imaging platform could play a role in the continued development of Lucid-MS, its investigational compound designed to inhibit demyelination by targeting protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation. Lucid-MS previously completed phase 1 clinical trials with a favorable safety profile, and the company submitted an Investigational New Drug (“IND”) application for a phase 2 trial to the U.S. Food and Drug Administration in March 2026.

For a company such as Quantum BioPharma, this type of progress represents more than a procedural checkbox. Multiple sclerosis affects more than 2.8 million people worldwide, and while treatments exist to manage the immune response, no therapy has yet demonstrated the ability to reliably halt or reverse the underlying nerve damage that drives long-term disability. The combination of a novel imaging tool that can directly visualize that damage and a drug candidate designed to address it at the source puts Quantum BioPharma in a distinctive position. Reaching the halfway point in enrollment, with early imaging data already showing meaningful impact, suggests the science is holding up under real-world clinical conditions, and that the path toward a more complete picture of both the disease and the therapy’s potential is coming steadily into view.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• Safe Pro Group Inc. (NASDAQ: SPAI) has announced that it has delivered against a recent $742,000 U.S. Army order for the company’s Threat Analysis Kits.
• The delivered kits include Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”), Black Widow drones from Red Cat Holdings, annual AI model and algorithm software upgrades and operational field analysis support.
• Safe Pro was awarded the subcontract and order from a Defense Prime Contractor on behalf of the Army which is seeking field-ready battlefield intelligence capability powered by advanced AI technology.

Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company that develops AI-powered security and defense solutions, recently announced that it has rapidly delivered against a U.S. Army order for Threat Analysis Kits under an award valued at around $742,000 (https://ibn.fm/smCGt).

The Threat Analysis Kit includes Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”) and Black Widow drones from Red Cat Holdings. It also features annual AI model and algorithm software upgrades and field support.

Safe Pro Group was recently awarded the subcontract from a Defense Prime Subcontractor and contracted to provide the U.S. Army with a turnkey, field-ready battlefield intelligence capability powered by its patented AI technology that processes the video and images captured by the Black Widow drones. It was also contracted to provide upgrades, training, and operational support.

Safe Pro anticipates that the training of U.S. Army personnel will take place before the end of June, and it will be providing support throughout the third quarter of 2026 and through upcoming planned exercises.

The NODE edge compute system, which is powered by Safe Pro’s Safe Pro Object Threat Detection (“SPOTD”) technology, uses AI and machine learning to identify small and easily missed threats like mines, cluster munitions, ambush drones, and unexploded ordnance (“UXO”). The platform is capable of identifying over 150 different threats across large-scale and high-risk environments.

It also operates on the edge without any need for connectivity and enables better battlefield situational awareness as it provides the rapid generation of things like vegetation height, terrain, slope, digital surface maps, and 3D models.

Safe Pro’s technology converts raw visual data into high-resolution and shareable maps and offers a scalable approach to battlefield awareness. The dataset contains more than 2.8 million drone images and has achieved over 50,368 confirmed detections across more than 35,000 acres of land in Ukraine.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that delivers AI-powered security and defense solutions to customers within industries like homeland security, law enforcement, defense, humanitarian, and commercial markets. At the center of Safe Pro’s mission is a patented computer vision software technology which rapidly detects small objects in drone imagery and video, to help enable safer and more efficient field operations for ground teams.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• The 10 cities with the largest police departments in the United States have paid out $1.02 billion for settlements and court judgements in police misconduct cases, with most centered around the improper use of force
• Wrap Technologies is well-positioned to establish a commanding position in supplying non-lethal tools to law enforcement departments globally
• Over 140 police departments across the United States received BolaWrap products in 2019, along with police departments in 19 other countries
• The company has received over 1,700 requests for demos, training and quotes from U.S. police departments, as well as over 600 requests from international markets
• Wrap Technologies can currently manufacture up to 1,800 BolaWrap devices per month, with plans to expand production capacity to 3,600 per month
• BolaWrap leverages strong intellectual product, with five U.S. patents granted and a further eight U.S. patents pending; the company has also filed four trademarks and has patents pending in 34 additional countries
• The addressable market size for non-lethal weapons is forecast to grow in size to $11.85 billion by 2023 (versus $6.32 billion in 2016)
• The company successfully raised $12.4 million through a primary share equity placement in June 2020, with proceeds destined to scale engineering, fund product development and provide working capital

Wrap Technologies (NASDAQ: WRAP) is an innovator of modern policing solutions. The company’s BolaWrap(R) product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (https://ibn.fm/ydMmC). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (https://ibn.fm/5HV8F). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (https://ibn.fm/I7lfP).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

• “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
• “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.”– Redditt Hudson, Regional Field Director of the NAACP (https://ibn.fm/VV3gw)
• “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
• “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be used to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (https://ibn.fm/6g4HZ). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap(R) technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which​, ​through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation) and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• ExploreTech is an exploration technology company that originated at Stanford University, developing an approach to exploration planning that’s more efficient than traditional methods.
• ExploreTech’s probabilistic modeling and drill planning solution pinpoints targets below cover, achieving the same or better drilling results with fewer boreholes.
• Recently, Canamera Energy Metals has engaged ExploreTech to deploy this technology at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

As the world becomes more reliant on technology and makes the shift to clean-energy, the critical metals they rely on are becoming more and more sought after. This increased demand requires a more efficient and effective approach to discover and delineate minerals.

ExploreTech, a Stanford-originated exploration technology company, has developed amore efficient approach to exploration planning than what’s currently available, and demonstrated this technology on over 15 partner projects. The company has shown excellent results, intersecting its predicted targets at every project drilled so far. 

In preparation for its drilling campaign, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), a rare earth and critical metals exploration company, has engaged ExploreTech to conduct an independent data review and drill optimization at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

ExploreTech will deploy the company’s proprietary ExploreTech Engine, which is a computing platform that runs probabilistic modeling workflows, to optimize capital spend and refine the depth extent and geometry of the four flagship priority target areas at the Project, which are Goldfinch, Blue Jay, Blackbird, and Starling. 

It’ll also optimize drill collar placement and deliver a ranked, phased drilling sequence in support of Canamera’s recommended 1,500 meter, nine-hole helicopter-supported diamond drilling program.

Speaking about the engagement, Brad Brodeur, CEO of Canamera Energy Metals, said that “Engaging ExploreTech brings a quantitative, evidence-weighted layer to our drill targeting that complements the technical work already completed by the Independent Qualified Person and the Project’s prior operators. ExploreTech’s track record speaks for itself, and partnering with them is consistent with our broader commitment to deploying best-in-class tools across the portfolio to maximize the return on every metre of drilling.”

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.